SyVento and OncoArendi have signed a joint development collaboration and exclusive global licensing agreement for the use of the nanoliposomal formulation of the arginase inhibitor OATD-02.
Details in following press release.
September 27, 2023
SyVento BioTech Participates in the Polish-British Future of Healthcare EventLONDON, September 26, 2023 – The Polish-British Future of Healthcare Event, focusing on advancements in MedTech, BioTech, and scientific research, will soon take place at the Royal Society of Medicine. SyVento BioTech will be represented by Tomasz Piec, Chairman of the Supervisory Board, and Dominik Lipka, our CTO. International Cooperation in BioTech: A Business Imperative […]